Company Encyclopedia
View More
name
Akebia Therap
AKBA.US
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.
1.946 T
AKBA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking38/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE361.07%A
    • Profit Margin-7.07%D
    • Gross Margin82.51%A
  • Growth ScoreA
    • Revenue YoY32.49%A
    • Net Profit YoY65.42%B
    • Total Assets YoY75.80%A
    • Net Assets YoY182.52%A
  • Cash ScoreC
    • Cash Flow Margin-1415.10%E
    • OCF YoY32.49%A
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreE
    • Gearing Ratio88.58%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Akebia Announces Establishment Of Rare Kidney Disease Pipeline

    Dec 1 (Reuters) - Akebia Therapeutics Inc:AKEBIA ANNOUNCES ESTABLISHMENT OF RARE KIDNEY DISEASE PIPELINEAKEBIA THERAPEUTICS: ACQUIRES NEXT GENERATION TISSUE-TARGETED C3D-FACTOR H FUSION PROTEIN COMPLEMENT INHIBITOR FROM Q32 BIOAKEBIA THERAPEUTICS: PHASE 2 BASKET TRIAL PLANNED TO EVALUATE COMPLEMENT INHIBITOR IN MULTIPLE RARE KIDNEY DISEASE INDICATIONSAKEBIA THERAPEUTICS INC: PHASE 2 TRIAL OF PRALICIGUAT INITIATED IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) AKEBIA THERAPEUTICS INC: BOTH TRIALS PLANNED TO START TREATING SUBJECTS IN 2026 Source text: Further company coverage:

    Reuters·
    US
    AKBA
    +1.27%
    Reuters·
    US
    AKBA
    +1.27%

    Q32 Bio shares are trading higher after the company sold its Phase 2 complement inhibitor ADX-097 to Akebia for $12 million upfront and potential milestone and royalty payments up to $592 million.

    benzinga_article·
    US
    AKBA
    +1.27%
    benzinga_article·
    US
    AKBA
    +1.27%

    Q32 Bio Sells ADX-097 to Akebia for Up to $592 Million

    Q32 Bio Inc. has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics for up to $592 million. The agreement includes $12 million in upfront and milestone payments, with potential additional payments tied to development, regulatory, and commercial milestones. Q32 Bio plans to use the proceeds to extend its cash runway into 2027 and focus on advancing bempikibart for alopecia areata.

    Reuters·
    US
    AKBA
    +1.27%
    Reuters·
    US
    AKBA
    +1.27%

    Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio

    Akebia Therapeutics Inc. has acquired global rights to AKB-097 from Q32 Bio through an Asset Purchase Agreement. Akebia paid $7 million upfront and will pay an additional $3 million after six months. The agreement includes potential milestone payments and tiered royalties on AKB-097 sales. This news was generated by Public Technologies using AI and is based on Akebia's original content published via GlobeNewswire.

    Reuters·
    US
    AKBA
    +1.27%
    Reuters·
    US
    AKBA
    +1.27%

    Akebia Therapeutics Updates License Agreement with Medice for Vafseo Supply and Manufacturing

    Akebia Therapeutics Inc. has amended its License Agreement with MEDICE Arzneimittel Pütter GmbH & Co. KG for the development and commercialization of Vafseo for anemia in chronic kidney disease patients in Europe and other regions. Akebia will supply vadadustat drug substance to Medice, which will manufacture Vafseo tablets. Any resulting know-how or patent rights will be owned by Akebia. The amendment will be filed with the Annual Report on Form 10-K for 2025.

    Reuters·
    US
    AKBA
    +1.27%
    Reuters·
    US
    AKBA
    +1.27%
    © 2025 Longbridge｜Disclaimer